JPMorgan Chase & Co’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.35M | Sell |
652,661
-120,556
| -16% | -$434K | ﹤0.01% | 3228 |
|
|
2025
Q1 | $2.31M | Buy |
773,217
+363,958
| +89% | +$1.09M | ﹤0.01% | 3169 |
|
|
2024
Q4 | $1.37M | Buy |
409,259
+314,015
| +330% | +$1.05M | ﹤0.01% | 3606 |
|
|
2024
Q3 | $319K | Buy |
95,244
+49,028
| +106% | +$164K | ﹤0.01% | 4255 |
|
|
2024
Q2 | $153K | Sell |
46,216
-57,040
| -55% | -$189K | ﹤0.01% | 4395 |
|
|
2024
Q1 | $417K | Buy |
103,256
+34,830
| +51% | +$141K | ﹤0.01% | 4065 |
|
|
2023
Q4 | $209K | Buy |
68,426
+29
| +0% | +$88 | ﹤0.01% | 4426 |
|
|
2023
Q3 | $205K | Buy |
68,397
+5,500
| +9% | +$16.5K | ﹤0.01% | 4224 |
|
|
2023
Q2 | $235K | Buy |
62,897
+684
| +1% | +$2.56K | ﹤0.01% | 4190 |
|
|
2023
Q1 | $208K | Sell |
62,213
-147,805
| -70% | -$494K | ﹤0.01% | 4304 |
|
|
2022
Q4 | $1.01M | Buy |
210,018
+24,974
| +13% | +$120K | ﹤0.01% | 3344 |
|
|
2022
Q3 | $1.05M | Buy |
185,044
+140,439
| +315% | +$799K | ﹤0.01% | 3311 |
|
|
2022
Q2 | $317K | Sell |
44,605
-174,995
| -80% | -$1.24M | ﹤0.01% | 4104 |
|
|
2022
Q1 | $1.59M | Buy |
219,600
+173,680
| +378% | +$1.25M | ﹤0.01% | 3329 |
|
|
2021
Q4 | $411K | Buy |
45,920
+2,070
| +5% | +$18.5K | ﹤0.01% | 4172 |
|
|
2021
Q3 | $1.54M | Buy |
43,850
+16,143
| +58% | +$566K | ﹤0.01% | 3327 |
|
|
2021
Q2 | $596K | Buy |
27,707
+19,509
| +238% | +$420K | ﹤0.01% | 3899 |
|
|
2021
Q1 | $506K | Sell |
8,198
-30,928
| -79% | -$1.91M | ﹤0.01% | 4035 |
|
|
2020
Q4 | $1.63M | Buy |
+39,126
| New | +$1.63M | ﹤0.01% | 3089 |
|